CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment

被引：7

作者：

Bao, Shunshun ^{[1
]}

Darvishi, Mohammad ^{[2
]}

Amin, Ali ^{[3
,4
]}

Al-Haideri, Maysoon T. ^{[5
]}

Patra, Indrajit ^{[6
]}

Kashikova, Khadisha ^{[7
]}

Ahmad, Irfan ^{[8
]}

Alsaikhan, Fahad ^{[9
]}

Al-qaim, Zahraa Haleem ^{[10
]}

Al-Gazally, Moaed E. ^{[11
]}

Kiasari, Bahman Abedi ^{[12
]}

Tavakoli-Far, Bahareh ^{[13
,14
]}

Sidikov, Akmal A. ^{[15
]}

Mustafa, Yasser Fakri ^{[16
]}

Akhavan-Sigari, Reza ^{[17
,18
]}

机构：

[1] Xuzhou Med Univ, Clin Med Coll 1, Xuzhou 221000, Peoples R China

[2] AJA Univ Med Sci, Infect Dis & Trop Med Res Ctr IDTMRC, Dept Aerosp & Subaquat Med, Tehran, Iran

[3] Umm Al Qura Univ, Deanship Sci Res, Mecca 21955, Saudi Arabia

[4] Mansoura Univ, Fac Sci, Zool Dept, Mansoura 35516, Egypt

[5] Cihan Univ Erbil, Dept Physiotherapy, Erbil, Kurdistan Regio, Iraq

[6] Natl Inst Technol Durgapur, Durgapur, W Bengal, India

[7] Kazakh Russian Natl Med Univ, Alma Ata, Kazakhstan

[8] King Khalid Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Abha, Saudi Arabia

[9] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Alkharj, Saudi Arabia

[10] Al Mustaqbal Univ Coll, Dept Anesthesia Tech, Hillah, Iraq

[11] Univ Al Ameed, Coll Med, Karbala, Iraq

[12] Univ Tehran, Fac Vet Med, Virol Dept, Tehran, Iran

[13] Alborz Univ Med Sci, Dietary Supplements & Probiot Res Ctr, Karaj, Iran

[14] Alborz Univ Med Sci, Fac Med, Dept Physiol & Pharmacol, Karaj, Iran

[15] Ferghana Med Inst Publ Hlth, Rector, Ferghana, Uzbekistan

[16] Univ Mosul, Coll Pharm, Dept Pharmaceut Chem, Mosul 41001, Iraq

[17] Univ Med Ctr Tuebingen, Dept Neurosurg, Tubingen, Germany

[18] Coll Humanum Warsaw Management Univ, Dept Hlth Care Management & Clin Res, Warsaw, Poland

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023年 / 149卷 / 10期

关键词：

CXCR4; CXCL12; axis; blockers; Cancer; Immunotherapy; CELL-DERIVED FACTOR-1-ALPHA; TO-MESENCHYMAL TRANSITION; PREDICTS POOR-PROGNOSIS; TUMOR-GROWTH; IN-VITRO; HEPATOCELLULAR-CARCINOMA; ANTI-CXCR4; ANTIBODY; PROSTATE-CANCER; SIGNALING AXIS; HEMATOPOIETIC STEM;

D O I：

10.1007/s00432-022-04444-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CXC chemokine receptor type 4 (CXCR4) is a member of the G protein-coupled receptors (GPCRs) superfamily and is specific for CXC chemokine ligand 12 (CXCL12, also known as SDF-1), which makes CXCL12/CXCR4 axis. CXCR4 interacts with its ligand, triggering downstream signaling pathways that influence cell proliferation chemotaxis, migration, and gene expression. The interaction also regulates physiological processes, including hematopoiesis, organogenesis, and tissue repair. Multiple evidence revealed that CXCL12/CXCR4 axis is implicated in several pathways involved in carcinogenesis and plays a key role in tumor growth, survival, angiogenesis, metastasis, and therapeutic resistance. Several CXCR4-targeting compounds have been discovered and used for preclinical and clinical cancer therapy, most of which have shown promising anti-tumor activity. In this review, we summarized the physiological signaling of the CXCL12/CXCR4 axis and described the role of this axis in tumor progression, and focused on the potential therapeutic options and strategies to block CXCR4.

引用

页码：7945 / 7968

页数：24

共 50 条

[1] CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment
Shunshun Bao
Mohammad Darvishi
Ali H Amin
Maysoon T. Al-Haideri
Indrajit Patra
Khadisha Kashikova
Irfan Ahmad
Fahad Alsaikhan
Zahraa Haleem Al-qaim
Moaed E. Al-Gazally
Bahman Abedi Kiasari
Bahareh Tavakoli-Far
Akmal A. Sidikov
Yasser Fakri Mustafa
Reza Akhavan-Sigari
[J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 7945 - 7968
[2] Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4)
Oishi, Shinya
Fujii, Nobutaka
[J]. ORGANIC & BIOMOLECULAR CHEMISTRY, 2012, 10 (30) : 5720 - 5731
[3] CXC chemokine receptor 4 (CXCR4) functions as a lactoferrin receptor in macrophages
Takayama, Y.
Aoki, R.
[J]. FEBS OPEN BIO, 2018, 8 : 376 - 376
[4] Blockade of chemokine receptor CXCR4 for the treatment of hepatocellular carcinoma metastasis
Kok, Tsz Wai
Yang, Zhenfan
Poon, Ronnie Tung Ping
[J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3503S - 3503S
[5] Drug Discovery Research Targeting the CXC Chemokine Receptor 4 (CXCR4)
Choi, Won-Tak
Duggineni, Srinivas
Xu, Yan
Huang, Ziwei
An, Jing
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (03) : 977 - 994
[6] Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices
Wescott, Melanie P.
Kufareva, Irina
Paes, Cheryl
Goodman, Jason R.
Thaker, Yana
Puffer, Bridget A.
Berdougo, Eli
Rucker, Joseph B.
Handel, Tracy M.
Doranz, Benjamin J.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (35) : 9928 - 9933
[7] Influence of chain length on the activity of tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4)
Baumann, Markus
Hussain, Mohammad Musarraf
Henne, Nina
Garrote, Daniel Moya
Karlshoj, Stefanie
Fossen, Torgils
Rosenkilde, Mette M.
Vabeno, Jon
Haug, Bengt Erik
[J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (02) : 646 - 657
[8] The role of chemokine receptor CXCR4 in lung cancer
Gangadhar, Tara
Nandi, Suvobroto
Salgia, Ravi
[J]. CANCER BIOLOGY & THERAPY, 2010, 9 (06)
[9] Chemokine receptor CXCR4: Role in gastrointestinal cancer
Lombardi, Lucia
Tavano, Francesca
Morelli, Franco
Latiano, Tiziana Pia
Di Sebastiano, Pierluigi
Maiello, Evaristo
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 88 (03) : 696 - 705
[10] CXC chemokine receptor 4 (CXCR4) targeted gold nanoparticles potently enhance radiotherapy outcomes in breast cancer
Bhattarai, Shanta
Mackeyev, Yuri
Venkatesulu, Bhanu P.
Krishnan, Sunil
Singh, Pankaj K.
[J]. NANOSCALE, 2021, 13 (45) : 19056 - 19065

← 1 2 3 4 5 →